ArticleMikrochimica acta2026
Discrimination of the S-isomer of ofloxacin using nanozyme-enhanced immunochromatographic analysis based on a secondary antibody-modified Au@Pd nanozyme.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Ofloxacin, a fluoroquinolone antibiotic, is a significant contaminant in food products. Its levorotatory form (S-OFL) exhibits a bactericidal activity considerably higher than the dextrorotatory form (R-OFL) and is commonly employed in veterinary medicines. In this work, a highly sensitive immunochromatographic analysis (ICA) method for biologically active S-OFL was developed. A bimetallic core@shell Au@Pd nanozyme was synthesized to serve as the label. Thanks to its peroxidase-like catalytic activity, the nanozyme enhances the color signal on test strips, thereby improving assay sensitivity. The instrumental limit of detection and cutoff values were determined to be 1.4 pg/mL and 0.1 ng/mL, corresponding to 60- and 10-fold improvements compared with conventional gold nanoparticle-based ICA. The cross-reactivity with R-OFL was only 6.3%, demonstrating the high specificity toward target isomer. The ICA was successfully applied to detecting S-OFL in milk, achieving recoveries of 77-99%. The entire nanozyme-enhanced analysis can be completed within 20 min. This method shows potential for monitoring various toxicants in food products.
Indexed as
Identifiers
42258022What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.